We describe the production and functional characterization of 2 monocytic-cell-lineage-specific immunotoxins constructed with saporin emitoxin (SAP) from Saponaria officinalis. Interest in the production of these immunotoxins, of possible clinical relevance, has been raised by the availability of 2 MAbs of high specificity for circulating monocytes and M5b ANLL, thus envisaging their potential use in bone-marrow purging. SAP emitoxin was selected on the basis of the low cytotoxicity in unconjugated form, as opposed to highly specific cytotoxicity and favourable pharmacokinetical properties in the conjugated form. SPDP conjugation produced immunotoxins which retained serological specificity and protein-synthesis-inhibitory activity. The 2 immunotoxins did not interfere with bone-marrow progenitor-cell growth in a CFU-GM colony assay. On the contrary, they were capable of killing monocytic cells selectively, as demonstrated in phenotypical and functional assays. Thus these 2 novel immunotoxins appear to be promising reagents in purging autologous bone marrow prior to transplantation in patients suffering from monocytic leukaemia.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.2910490228DOI Listing

Publication Analysis

Top Keywords

m5b anll
8
immunotoxins
6
production characterization
4
characterization immunotoxins
4
immunotoxins specific
4
specific m5b
4
anll leukaemia
4
leukaemia describe
4
describe production
4
production functional
4

Similar Publications

Article Synopsis
  • T-lineage acute lymphoblastic leukemia (ALL) presents as an aggressive cancer with diverse subtypes, making traditional classification difficult.
  • A multiomics analysis of bone marrow samples revealed a specific subset of T-lineage ALL with active inflammatory and stem gene programs, showing unique biological and treatment response characteristics.
  • A computational inflammatory gene signature scoring system was developed to better classify patients, identifying a high-risk subtype that could guide targeted therapies for more effective treatment approaches.
View Article and Find Full Text PDF

Acute myeloid leukemia (AML) is the most aggressive hematopoietic malignancy characterized by uncontrolled proliferation of myeloid progenitor cells within the bone marrow. Tumor suppressor cylindromatosis (CYLD) is a deubiquitinating enzyme, which suppresses inflammatory response in macrophages. Macrophages have a central role in the defense against foreign substances and circulating cancer cells by their professional phagocytic capacity.

View Article and Find Full Text PDF

In March 2022, a 58-year-old man was admitted to the local hospital for nausea and vomiting. His blood routine indicated that he had leukocytosis and anemia. The patient was diagnosed with acute myeloid leukemia (AML)-M5b accompanied by , and mutations, chest CT revealed pulmonary tuberculosis (TB).

View Article and Find Full Text PDF
Article Synopsis
  • A 2-year-old boy was diagnosed with acute megakaryoblastic leukemia (AMKL) and achieved complete remission through chemotherapy without needing stem cell transplantation.
  • Nine months post diagnosis, he developed acute monocytic leukemia (AMoL), marked by the presence of the KMT2A::LASP1 chimeric gene, and again achieved complete remission after receiving multi-agent chemotherapy followed by cord blood transplantation.
  • Detailed analysis confirmed that AMoL was a separate leukemia rather than a relapse of AMKL, as indicated by differences in morphology, genomics, and molecular characteristics; the patient is now disease-free.
View Article and Find Full Text PDF

Acute myeloid leukemia (AML) with t(8;16) is a rare cytogenetic abnormality that presents unique characteristics such as hemophagocytosis, disseminated intravascular coagulation, leukemia cutis and varying levels of CD45 expression. It is more common in women and usually associated with prior cytotoxic therapies, accounting for <0.5% of all AML cases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!